Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
NCT00283478
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
Iscar Quercus
DRUG:
Gemcitabine
Sponsor
Kentuckiana Cancer Institute